1
|
Monk B, Brady M, Aghajanian C, Lankes H, Rizack T, Leach J, Fowler J, Higgins R, Hanjani P, Morgan M. A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
2
|
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol 2017; 28:996-1004. [PMID: 28453702 PMCID: PMC5406764 DOI: 10.1093/annonc/mdx049] [Citation(s) in RCA: 60] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death. PATIENTS AND METHODS Women with ovarian, fallopian tube, or primary peritoneal carcinoma were randomized 1 : 1 to receive PLD in combination with blinded motolimod or placebo. Randomization was stratified by platinum-free interval (≤6 versus >6-12 months) and Gynecologic Oncology Group (GOG) performance status (0 versus 1). Treatment cycles were repeated every 28 days until disease progression. RESULTS The addition of motolimod to PLD did not significantly improve overall survival (OS; log rank one-sided P = 0.923, HR = 1.22) or progression-free survival (PFS; log rank one-sided P = 0.943, HR = 1.21). The combination was well tolerated, with no synergistic or unexpected serious toxicity. Most patients experienced adverse events of fatigue, anemia, nausea, decreased white blood cells, and constipation. In pre-specified subgroup analyses, motolimod-treated patients who experienced injection site reactions (ISR) had a lower risk of death compared with those who did not experience ISR. Additionally, pre-treatment in vitro responses of immune biomarkers to TLR8 stimulation predicted OS outcomes in patients receiving motolimod on study. Immune score (tumor infiltrating lymphocytes; TIL), TLR8 single-nucleotide polymorphisms, mutational status in BRCA and other DNA repair genes, and autoantibody biomarkers did not correlate with OS or PFS. CONCLUSIONS The addition of motolimod to PLD did not improve clinical outcomes compared with placebo. However, subset analyses identified statistically significant differences in the OS of motolimod-treated patients on the basis of ISR and in vitro immune responses. Collectively, these data may provide important clues for identifying patients for treatment with immunomodulatory agents in novel combinations and/or delivery approaches. TRIAL REGISTRATION Clinicaltrials.gov, NCT 01666444.
Collapse
Affiliation(s)
- B. J. Monk
- Arizona Oncology (US Oncology Network), University of Arizona, College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix
| | - M. F. Brady
- GOG Foundation Statistical and Data Center, Roswell Park Cancer Institute, Buffalo
| | - C. Aghajanian
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York
| | - H. A. Lankes
- GOG Foundation Statistical and Data Center, Roswell Park Cancer Institute, Buffalo
| | - T. Rizack
- Women & Infants Hospital, Alpert Medical School of Brown University, Providence
| | - J. Leach
- Metro-Minnesota Community Oncology Research Consortium, Minneapolis
| | | | - R. Higgins
- Carolinas Medical Center Levine Cancer Institute, Charlotte
| | - P. Hanjani
- Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington
| | - M. Morgan
- University of Pennsylvania Health System, Philadelphia
| | - R. Edwards
- University of Pittsburgh Medical Center, Pittsburgh
| | - W. Bradley
- The Medical College of Wisconsin, Milwaukee
| | - T. Kolevska
- Kaiser Permanente Medical Center–Vallejo, Vallejo
| | - P. Foukas
- Ludwig Institute for Cancer Research, Lausanne
| | | | | | - R. Gottardo
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle
| | | | | | | | - R. S. Mannel
- The Oklahoma University College of Medicine, Oklahoma City, USA
| | | | - G. Coukos
- Ludwig Institute for Cancer Research, Lausanne
| |
Collapse
|
3
|
Banerjee N, Kamalakaran S, Varadan V, Janevski A, Lezon-Geyda K, Bossuyt V, Flowers D, Sikov W, Abu-Khalaf M, Rizack T, Harris L, Dimitrova N. P3-06-04: Sno/miRNA Expression Via Next Generation Sequencing: Variation in Patients before and after Treatment. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Aberrant expression of small RNA molecules has been shown in breast cancer. It is yet unclear if variation exists in small RNA molecule expression in response to treatment. Since next generation sequencing offers more globally sensitive detection of sno and miRNAs, we performed an RNA-seq study to explore patients pre- and post- brief exposure to treatment.
Methods: We sequenced transcriptomes of frozen biopsy samples from 8 breast cancer patients enrolled in a clinical trial for neoadjuvant therapy using trastuzumab (HER2 positive) or bevacizumab (HER2 negative) with chemotherapy. Tumor core biopsies were taken before and after 10 days of either biologic or nab-paclitaxel treatment and stored in OCT compound. Total RNA was extracted and libraries were constructed for the 16 samples using TruSeq (Illumina). We performed 74bp paired-end sequencing with the Illumina GAII platform. Sequences were aligned to the sno/miRNA track (containing 928 miRNAs and 413 snoRNAs) in UCSC and read counts were determined using Bowtie. We performed differential miRNA and snoRNA expression analysis pair-wise in all pre- and post-therapy samples. Given that miRNA deregulation relies on their protein-coding gene targets, we analyzed the predicted targets of the significantly varying miRNAs for functional enrichment.
Results: Each sample had on average 46 million paired-end reads, of which on average 70% were mapped to the human genome. Overall, we detected 138 miRNAs in at least one sample, with each sample expressing 33 miRNAs on average. We detected a total of 11 miRNAs (7%) that showed significant differential expression with treatment. Interestingly, 6 of these miRNAs varied in all patients. The predicted targets of these miRNAs were enriched in DNA-dependent transcription, gene expression, cell proliferation and cell communication. Similarly, we detected 202 snoRNAs in at least one sample, with each sample expressing 87 snoRNAs on average. Of these, we found 21 snoRNAs (10%) to vary significantly upon treatment and 6 of these snoRNAs showed expression changes in all patients.
Conclusions: These results suggest that variation in sno/miRNA expression may play a role in response to treatment. The consistent variation of sno/miRNAs in response to treatment suggests shared small RNA-mediated mechanisms. If validated, these results suggest that next generation sequencing technologies will allow lead to improved methods of stratifying, subclassifying and managing breast cancer.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-06-04.
Collapse
Affiliation(s)
- N Banerjee
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - S Kamalakaran
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - V Varadan
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - A Janevski
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - K Lezon-Geyda
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - V Bossuyt
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - D Flowers
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - W Sikov
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - M Abu-Khalaf
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - T Rizack
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - L Harris
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - N Dimitrova
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| |
Collapse
|
4
|
Varadan V, Kamalakaran S, Janevski A, Banerjee N, Lezon-Geyda K, Bossuyt V, Flowers D, Sikov W, Abu-Khalaf M, Rizack T, Dimitrova N, Harris LN. P3-06-01: Next Generation RNA Sequencing Reveals Changes in Gene Expression and Alternative Splicing upon Brief Exposure to Therapy in Early Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The use of next generation RNA sequencing (RNA-seq) allows for the characterization of the transcriptome at levels of detail unachievable by array-based technologies. RNA-seq analysis can quantify expression of novel transcripts and alternatively spliced isoforms in addition to known genes. Alternative splicing allows for flexibility in production of protein isoforms and is frequently dysregulated in cancer. As splice variants may play a role in response to therapy (Solier, et al, Cancer Res., 2010), we studied differential gene and isoform expression in breast cancers after one dose of treatment, prior to a course of preoperative therapy.
Methods: We sequenced transcriptomes of core biopsy samples from 8 breast cancer patients enrolled in a preoperative clinical trial using trastuzumab (HER2 positive) or bevacizumab (HER2 negative) with chemotherapy. Tumor core biopsies were taken before and after 10 days of either biologic or nab-paclitaxel treatment and stored in OCT compound. Total RNA was extracted, amplified and libraries were constructed for the 16 samples using TruSeq (Illumina). Paired-end sequencing was performed on the Illumina GAII platform with read length of 74bp. Sequence data was mapped using TopHat and transcript abundance in FPKM units (Fragments per kilo-base of mRNA per million reads) estimated for a total of 22,160 unique genes and 34,449 unique transcripts from RefSeq. Differential expression of transcripts between baseline and 10-day samples was estimated using t-statistics with read-counts modeled as a Poisson distribution. Differentially expressed transcripts were selected at a significance level of 0.05 after multiple testing correction.
Results: Each sample had on average 46 million paired-end reads, of which on average 70% were mappable to the human reference genome (UCSC, hg19). A median of 138 (range 68–948) transcripts varied with treatment. GO analysis showed enrichment of cell-adhesion, apoptosis, differentiation and cell proliferation pathways. Interestingly, the isoforms of several known cancer genes such as TP53 were seen in all treatment types. Certain isoforms were only seen to change upon brief exposure to chemotherapy such as BCL2 whereas TNF ligand and PCDH isoforms showed significant change only with biologic agents.
Conclusions: These results suggest that recurrent changes in both canonical genes and splice variants occur over the course of treatment in early breast cancer. This underscores the value of RNA-seq to provide novel information that may be clinically useful. Brief exposure to monotherapy prior to combination treatment may provide important mechanistic insights and produce predictive biomarkers. Biologic treatments may produce unique changes that can only be discovered with novel next generation sequencing techniques.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-06-01.
Collapse
Affiliation(s)
- V Varadan
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - S Kamalakaran
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - A Janevski
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - N Banerjee
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - K Lezon-Geyda
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - V Bossuyt
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - D Flowers
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - W Sikov
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - M Abu-Khalaf
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - T Rizack
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - N Dimitrova
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| | - LN Harris
- 1Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Brown University School of Medicine, Providence, RI
| |
Collapse
|
5
|
Kamalakaran S, Lezon-Geyda K, Varadan V, Banerjee N, Lannin DR, Rizack T, Sikov WM, Abu-Khalaf MM, Janevski A, Harris L. Evaluation of ER/PR and HER2 status by RNA sequencing in tissue core biopsies from preoperative clinical trial specimens. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.46] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
46 Background: Next-generation sequencing for measuring RNA (RNASeq) offer increased sensitivity, dynamic range and provide unbiased detection of all transcripts. To evaluate the clinical utility of such methods, we sequenced entire transcriptomes from fresh-frozen biopsies in a cohort of 120 patients enrolled on a preoperative therapy trial receiving carboplatin, nab paclitaxel and either bevacizumab (HER2-) or trastuzumab (HER2+). Methods: Total RNA was extracted and amplified from frozen breast core biopsies and libraries constructed using TruSeq (Illumina). Sequencing was performed on the Illumina GAII platform. 75bp reads were mapped using Tophat and transcript abundance in FPKM units (Fragments per kilo-base of mRNA per million reads) calculated using Cufflinks. CLIA approved assays were performed for ER, PR, HER2 (IHC+/- FISH) on patient tumors. Four tumors from each subtype (ER +ve/HER2 -ve; HER2 +ve; ER/HER2 -ve) were analyzed for correlation with clinical status. PAM50 classification will be provided for verification of molecular subtypes. Results: RNA-Seq library construction/sequencing were successful in 12/12 samples with 50-90% reads mapped. ER +ve tumors ranged in FPKM values from 1.76-22.67 and ER -ve tumors ranged from 0.00-0.79. i.e. ER RNASeq measurements can separate clinical ER status. HER2 +ve tumors ranged in FPKM values from 2.62-21.71 and HER2 -ve tumors from 0.21-1.79. Of note, 7/8 HER2 -ve tumors ranged from 0.21-0.87 with one ‘outlier’ at 1.79±0.3. This outlier was HER2 IHC 2+, FISH ratio 1.1 with 45% of tumor cells with polysomy chromosome 17. Correspondence of ER/PR and HER2 status with molecular subtyping by PAM50 analysis will be presented. Conclusions: RNASeq has potential to provide in depth analysis of the breast cancer transcriptome and a single analysis test for standard markers. In addition, RNASeq may uncover unexpected expression patterns in conventionally-defined HER2 -ve tumors. If reproducible in larger datasets, this technology may provide both standard and novel information previously unavailable to oncologists and their patients.
Collapse
Affiliation(s)
- S. Kamalakaran
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - K. Lezon-Geyda
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - V. Varadan
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - N. Banerjee
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - D. R. Lannin
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - T. Rizack
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - W. M. Sikov
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - M. M. Abu-Khalaf
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - A. Janevski
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | - L. Harris
- Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Women and Infants Hospital of Rhode Island, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI
| | | |
Collapse
|
6
|
Sinclair N, Abu-Khalaf MM, Sakr BJ, Rizack T, Lannin DR, Gass JS, Strenger R, Bossuyt V, Fenton MA, Harris L, Sikov WM. Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Rizack T, Abu-Khalaf MM, Legare RD, Strenger R, Fenton MA, Sakr BJ, Kennedy TA, Harris L, Sikov WM. Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: Interim dose delivery and toxicity data. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Dizon DS, Gass J, Legare RD, Sakr BJ, Rizack T. Is tumor board relevant? J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Rizack T, Mega A, Berz D. Is squamous cell histology an adverse prognosticator for survival of malignancies of the upper urinary tract? J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6617 Background: Carcinomas of the renal pelvis and ureter are rare diseases, accounting for only about 1% of all urogenital malignancies. Previous reports suggest that squamous cell histology is associated with inferior survival. We present the largest population based analysis to date of survival in patients with upper urinary tract malignancies. Methods: We analyzed the Surveillance, Epidemiology and End Results database for cancer specific survival rates in patients with renal pelvis and ureteral malignancies who were diagnosed between 1973 and 2003 in the SEER catchment geographic areas. The primary exposure of interest was the underlying histology, squamous cell versus transitional cell differentiation. We performed descriptive statistics, non parametric survival analysis, and cox proportional hazard analysis. Results: We identified 13,213 eligible patients, 7,716 renal pelvis and 5,497 ureteral carcinomas. Among this cohort, 179 patients had squamous cell carcinoma (SCC), 12,395 had transitional cell carcinoma (TCC), including 121 papillary, and 619 had other histologies. Overall, patients with SCC histology fared worse. The median overall survival time was 10 months for SCC and 63 months for TCC. The cox analysis revealed a HR 0.42 (95% CI 0.36–0.47) for TCC when compared to SCC and corrected for decade of diagnosis, age, gender, prior treatment, and race. The difference between the two groups was entirely attributable to survival differences in patients with loco-regional disease. However, when stratified by lymph node involvement this difference disappeared for patients with locally involved lymph nodes (p = 0.84) and for patients with clear lymph nodes (p = 0.92). Conclusions: SCCs of the upper urinary tract present at a higher clinical stage and appear to represent more aggressive disease when compared to other histologies. However, when appropriately staged according to lymph node status, the survival of TCC and SCC of the upper urinary tract is identical when compared stage by stage. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - A. Mega
- Brown University, Providence, RI
| | - D. Berz
- Brown University, Providence, RI
| |
Collapse
|